Literature DB >> 8389705

Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.

M Pfaller1, A Barry, P Fuchs, E Gerlach, D Hardy, J McLaughlin.   

Abstract

Three beta-lactamase inhibitors were combined with ampicillin in a fixed 2:1 ratio. The activity of ampicillin was enhanced by tazobactam and by clavulanic acid, and to a lesser extent by sulbactam when tested against fresh clinical isolates of Enterobacteriaceae. At a concentration of 8 micrograms/ml, ampicillin alone inhibited 49.6% of 2,434 consecutive isolates of enteric bacilli compared to 81% inhibited by ampicillin combined with tazobactam or clavulanic acid and 69.3% inhibited by the sulbactam/ampicillin combination. A four-fold or greater reduction in ampicillin MICs was observed in comparable numbers of isolates with all three combinations, but the most marked effects were seen with strains that were highly resistant to ampicillin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389705     DOI: 10.1007/bf01967112

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.

Authors:  S Mehtar; Y J Drabu; P H Blakemore
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

2.  Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.

Authors:  F Moosdeen; J D Williams; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

3.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

Authors:  G M Eliopoulos; K Klimm; M J Ferraro; G A Jacoby; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

5.  Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

6.  Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Authors:  R N Jones; M A Pfaller; P C Fuchs; K Aldridge; S D Allen; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

7.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

Authors:  R J Fass; R B Prior
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

9.  In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

View more
  2 in total

1.  Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection.

Authors:  P J Cook; J M Andrews; J Woodcock; R Wise; D Honeybourne
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

Review 2.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.